rotaviru
import
etiolog
agent
sever
gastroenter
previous
report
skim
concentr
bovin
late
colostrum
scblc
obtain
normal
unimmun
cow
parturit
effect
prevent
human
rotaviru
hrv
induc
sever
gastroenter
vivo
administ
singl
dose
min
viral
inocul
present
studi
examin
efficaci
multipl
administr
scblc
smaller
dosag
viral
inocul
vivo
demonstr
multipl
administr
within
h
viru
inocul
result
earlier
recoveri
diarrheal
symptom
administr
frequencydepend
manner
furthermor
investig
whether
isol
igg
antihrv
activ
scblc
equival
igg
isol
bovin
matur
milk
measur
vitro
activ
assay
found
iggcontain
fraction
scblc
matur
milk
exhibit
approxim
level
antihrv
activ
conclud
scblc
contain
high
level
igg
hrvinduc
sever
gastroenter
possibl
use
protect
effect
immunocompromis
host
children
elderli
multipl
dose
scblc
earli
stage
infect
lower
dosag
scblc
given
singl
dose
result
relief
diarrheal
symptom
human
rotaviru
hrv
major
viral
enteropathogen
lead
sever
dehydr
gastroenter
infant
young
children
worldwid
caus
death
annual
occur
develop
countri
center
diseas
control
prevent
reduc
signific
mortal
caus
pathogen
rotaviru
vaccin
rotateq
merck
co
whitehous
station
nj
rotarix
glaxosmithklin
biolog
rixensart
belgium
licens
incorpor
univers
immun
program
mani
countri
center
diseas
control
prevent
howev
first
dose
vaccin
strictli
limit
infant
age
wk
increas
risk
intussuscept
nakagomi
nakagomi
therefor
develop
altern
prophylact
approach
especi
nontimelimit
first
dose
requir
immunocompromis
host
ingest
hyperimmun
colostrum
propos
altern
prophylact
approach
hrv
gastroenter
ebina
et
al
sarker
et
al
hyperimmun
colostrumcontain
rotavirusspecif
neutral
igg
produc
immun
pregnant
holstein
cow
hrv
harvest
colostrum
deliveri
howev
difficult
gener
largescal
amount
hyperimmun
colostrum
furthermor
sale
earli
colostrum
cow
within
parturit
food
substanc
illeg
japan
recent
report
skim
concentr
pasteur
bovin
milk
healthi
lactat
cow
postparturit
refer
skim
concentr
bovin
late
colostrum
scblc
effect
prevent
hrvinduc
diarrhea
suckl
mice
indic
potenti
scblc
use
prophylact
food
addit
hrv
infect
inagaki
et
al
skim
concentr
bovin
late
colostrum
report
effect
protect
sever
type
viral
infect
murakami
et
al
uchida
et
al
uchida
et
al
exampl
murakami
et
al
demonstr
scblc
reduc
bind
viruslik
particl
noroviru
strain
sapoviru
strain
human
intestin
cell
concentrationdepend
manner
uchida
et
al
report
treatment
scblc
could
shorten
durat
diseas
upper
respiratori
tract
caus
viru
ie
rhinoviru
coronaviru
influenza
viru
clinic
trial
oral
administr
scblc
protect
influenza
viral
infect
activ
cellular
immun
vivo
use
mous
model
vitro
use
murin
peyer
patch
cell
uchida
et
al
find
support
hypothesi
ingest
scblc
protect
variou
viral
infect
studi
undertook
detail
investig
use
scblc
ingest
hrvinduc
diarrhea
suckl
mice
previous
multipl
oral
administr
per
day
chemic
synthes
sulfat
sialyl
lipid
shown
capabl
reduc
dosag
per
administr
necessari
achiev
protect
human
rotaviru
infect
mice
takahashi
et
al
gener
lower
dosag
per
administr
would
accept
immunocompromis
host
furthermor
demonstr
antihrv
activ
igg
correl
lactat
stage
previous
hypothes
protect
effect
scblc
hrv
gastroenter
due
presenc
igg
neutral
antibodi
demonstr
scblc
contain
larger
amount
igg
matur
milk
bind
hrv
neutral
african
rhesu
monkey
cell
kidney
cell
line
cultur
eagl
minim
essenti
medium
mem
supplement
fetal
calf
serum
fc
hrv
mo
strain
serotyp
hrv
wa
strain
serotyp
bovin
rotaviru
ncdv
strain
serotyp
propag
cell
viru
titer
determin
fluoresc
cell
focusform
unit
fcfu
assay
describ
previous
ebina
et
al
chemic
use
reagent
grade
mous
monoclon
igg
middl
layer
viru
protein
vp
pigeon
rotaviru
strain
serotyp
use
detect
infect
cell
prepar
report
previous
minamoto
et
al
fluorescein
isothiocyanateconjug
goat
antimous
igg
purchas
american
qualex
san
clement
ca
bovin
matur
milk
collect
healthi
holsteinfriesian
cow
held
gifu
univers
farm
gifu
japan
colostrum
whey
cow
hyperimmun
hrv
rota
whey
prepar
describ
previous
ebina
et
al
skim
concentr
bovin
late
colostrum
normal
cow
prepar
industri
level
facil
kobayashi
pharmaceut
osaka
japan
inagaki
et
al
briefli
pool
late
colostrum
healthi
cow
deliveri
defat
centrifug
pasteur
via
htst
condit
concentr
ultrafiltr
spray
dri
milk
protein
concentr
determin
bradford
protein
assay
kit
biorad
laboratori
inc
hercul
ca
use
bsa
standard
follow
manufactur
instruct
remov
casein
acid
precipit
ph
whey
protein
dissolv
mm
sodium
phosphat
buffer
ph
concentr
mg
ml
affin
chromatographi
perform
use
hitrap
protein
g
hp
ml
ge
healthcar
chalfont
st
gile
uk
column
equilibr
buffer
connect
control
prime
system
ge
healthcar
whey
load
onto
column
flow
rate
mlmin
elut
bound
protein
perform
use
elut
buffer
glycinehcl
buffer
ph
fraction
monitor
via
spectrophotometri
nm
protein
content
fraction
contain
elut
igg
fraction
neutral
trishcl
ph
freez
dri
dialysi
distil
water
use
previous
develop
mous
model
rotaviru
gastroenter
studi
protect
efficaci
develop
diarrhea
ebina
et
al
mice
balbc
pregnant
purchas
japan
slc
hamamatsu
japan
gave
birth
sever
day
later
litter
mice
averag
bw
g
oral
inocul
singl
dose
hrv
mo
strain
gavag
stool
examin
daili
everi
h
viru
inocul
develop
diarrhea
gentli
press
massag
abdomen
begin
postinocul
rank
system
diarrhea
index
di
use
character
diarrhea
takahashi
et
al
normal
brown
form
stool
stool
soft
orang
stool
liquid
yellow
stool
skim
concentr
bovin
late
colostrum
dissolv
pb
given
oral
suckl
mice
experiment
group
gavag
min
viral
inocul
control
mice
given
pb
ph
diarrhea
score
calcul
averag
diari
stool
observ
care
experiment
procedur
approv
anim
care
use
committe
gifu
univers
replic
inhibit
assay
hrv
mo
strain
carri
use
cell
describ
previous
ebina
et
al
suspens
contain
infecti
viru
titer
fcfuml
treat
trypsin
sigmaaldrich
st
loui
mo
min
appropri
dilut
mem
contain
fc
give
titer
approxim
fcfu
per
aliquot
serial
dilut
mem
contain
fc
sampl
incub
microtub
h
dilut
mixtur
use
inocul
cell
cellsml
addit
aliquot
place
well
heavi
teflonco
slide
ar
brown
co
ltd
tokyo
japan
control
cell
gave
infect
foci
per
well
replac
milk
sampl
mem
contain
fc
cell
cultur
h
atmospher
co
fix
cold
aceton
min
number
foci
well
contain
infect
cell
measur
use
indirect
immunofluoresc
assay
use
monoclon
antibodi
pigeon
rotaviru
minamoto
et
al
fluorescein
isothiocyanateconjug
antimous
igg
goat
serum
neutral
activ
express
percentag
reduct
foci
number
infect
cell
observ
fluoresc
microscopi
mic
minimum
concentr
show
reduct
infect
cell
calcul
sampl
logarithm
regress
concentrationdepend
percentag
foci
reduct
virusbind
radio
immunoprecipit
assay
ripa
perform
radiolabel
hrv
wa
bovin
rotaviru
ncdv
strain
confluent
wa
straininfect
cell
radiolabel
kbq
smethionin
h
atmospher
co
wash
cold
pb
time
cell
incub
ripa
buffer
mm
tri
mm
sodium
chlorid
mm
edta
tritonx
sodium
deoxychol
aprotinin
mm
phenylmethylsulfonyl
fluorid
min
ice
homogen
homogen
solut
centrifug
g
min
result
supernat
use
radiolabel
viru
bovin
colostrum
igg
pb
mix
vortex
radiolabel
viru
microtub
room
temperatur
addit
protein
gsepharos
protein
gsepharos
ripa
buffer
volvol
ge
healthcar
microtub
incub
h
ice
iggprotein
gsepharos
complex
collect
centrifug
g
second
wash
ripa
buffer
time
follow
wash
pb
sodium
dodecyl
sulfat
page
perform
use
laemmli
method
laemmli
iggprotein
gsepharos
complex
boil
min
sdspage
sampl
buffer
presenc
centrifug
supernat
subject
sdspage
separ
protein
gel
fix
immers
sodium
salicyl
soak
glycerol
gel
dri
imag
perform
bioimag
analyz
fujix
fujifilm
tokyo
japan
statist
analysi
mice
diarrhea
experi
perform
use
mannwhitney
u
test
analysi
varianc
use
examin
differ
scblc
pb
signific
set
p
data
text
mean
standard
deviat
statist
analysi
vitro
experi
perform
use
welch
ttest
initi
examin
hrv
titer
requir
induct
gastroenter
symptom
suckl
mice
litter
balbc
mice
oral
inocul
differ
titer
hrv
mo
strain
fcfu
respect
via
singl
administr
control
mice
receiv
equival
volum
pb
mice
inspect
characterist
diarrhea
gentl
palpat
abdomen
h
postinocul
hpi
hrvinduc
diarrhea
symptom
suckl
mous
model
overt
hpi
ebina
et
al
shown
tabl
mockinfect
control
mice
exhibit
diarrheal
symptom
wherea
major
mice
inocul
hrv
sever
diarrhea
regardless
viral
titer
howev
observ
viral
titer
fcfumous
led
decreas
incid
diarrhea
adopt
highest
viral
titer
fcfumous
ensur
diarrhea
induc
assess
effect
dosag
scblc
prevent
hrvinduc
diarrhea
singl
administr
litter
suckl
mice
oral
given
mg
scblc
pb
min
inocul
hrv
mo
strain
control
mice
given
pb
di
calcul
averag
diari
stool
observ
shown
figur
control
group
observ
mice
present
diarrhea
hpi
di
still
suffer
diarrhea
hpi
di
convers
group
receiv
mg
scblc
mice
develop
diarrhea
hpi
di
similarli
group
receiv
mg
scblc
mice
develop
diarrhea
half
mice
present
soft
orang
stool
hpi
di
almost
half
mice
given
mg
scblc
suffer
diarrhea
hpi
di
although
mice
recov
diarrhea
mice
suffer
soft
brown
stool
hpi
di
therefor
found
singl
administr
mg
scblc
significantli
protect
hrvinduc
diarrhea
wherea
mg
scblc
statist
signific
effect
singl
administr
evalu
effect
administr
frequenc
lowerdos
multipl
administr
scblc
use
nonprotect
dosag
shown
figur
three
differ
administr
interv
scheme
indic
arrow
box
figur
first
dose
given
oral
min
viral
inocul
addit
dose
given
oral
gavag
hpi
hpi
hpi
time
viral
inocul
control
mice
given
pb
gavag
time
di
calcul
averag
diari
stool
observ
shown
figur
control
group
mice
develop
diarrhea
hpi
di
half
still
present
soft
orang
stool
hpi
di
comparison
scblc
group
observ
mice
given
scblc
present
similar
diarrheal
symptom
level
un
til
hpi
di
experienc
mild
reduct
symptom
administr
frequencydepend
manner
hpi
onward
group
receiv
administr
scblc
experienc
signific
reduct
symptom
hpi
di
p
hpi
di
p
indic
administr
frequenc
scblc
within
first
hpi
import
reliev
diarrheal
symptom
evalu
minimum
effect
dosag
given
multipl
administr
effect
reduc
diarrheal
symptom
investig
differ
dosag
amount
scblc
mg
gave
singl
administr
scblc
viral
inocul
follow
administr
within
hpi
min
viral
inocul
hpi
control
mice
given
pb
administr
schedul
diarrhea
score
calcul
averag
daili
stool
observ
shown
figur
pb
group
mice
develop
diarrhea
hpi
di
thereaft
mice
present
soft
brown
stool
hpi
di
mg
dose
similar
symptom
level
di
observ
hpi
follow
symptom
level
hpi
respect
contrast
mg
dosag
mice
present
di
hpi
di
mice
recov
sever
diarrhea
hpi
di
final
di
hpi
reduc
result
indic
minimum
effect
dosag
mg
scblc
multipl
administr
within
hpi
necessari
reliev
hrvinduc
diarrhea
suckl
mice
effect
dose
scblc
multipl
administr
analyz
detail
shown
figur
panel
summari
symptomat
diarrhea
three
administr
everi
h
viral
inocul
adapt
figur
mice
present
soft
orang
stool
di
hpi
still
soft
stool
symptom
panel
b
show
summari
symptomat
diarrhea
three
administr
within
h
viral
inocul
adapt
figur
five
mice
develop
liquid
yellow
diarrhea
di
hpi
mice
still
present
soft
orang
stool
di
hpi
panel
c
show
summari
symptomat
diarrhea
five
administr
everi
h
viral
inocul
administr
within
hpi
administr
hpi
onward
adapt
figur
half
mice
develop
soft
orang
diarrhea
di
hpi
mice
recov
hpi
comparison
scheme
present
panel
panel
c
figur
suggest
multipl
administr
within
hpi
reliev
diarrheal
symptom
hpi
onward
furthermor
comparison
scheme
present
panel
b
panel
c
suggest
repetit
administr
hpi
onward
import
earli
recoveri
hrvinduc
diarrhea
hpi
n
solid
triangl
time
hpi
n
open
circl
control
mice
given
pb
gavag
time
stool
examin
daili
assess
diarrhea
hpi
diarrhea
character
use
diarrhea
index
di
normal
brown
form
stool
stool
soft
orang
stool
liquid
yellow
stool
point
repres
mean
sd
open
arrow
box
figur
indic
time
point
dose
scblc
administ
start
min
viral
inocul
close
arrow
indic
time
point
dose
scblc
administ
viral
inocul
p
determin
mannwhitney
u
test
skim
concentr
bovin
late
colostrum
contain
larg
amount
immunoglobulin
compar
abil
igg
scblc
matur
milk
reduc
hrvinduc
diarrheal
symptom
isol
examin
purifi
igg
scblc
matur
milk
igg
isol
use
affin
chromatographi
protein
g
column
confirm
igg
isol
perform
use
page
heavi
light
chain
igg
detect
coomassi
brilliant
blue
data
shown
shown
figur
scblc
exhibit
inhibitori
activ
hrv
mic
contrast
mic
matur
milk
approxim
time
weaker
scblc
isol
igg
scblc
show
strong
inhibitori
activ
hrv
mic
figur
effect
multipl
administr
vari
dose
skim
concentr
bovin
late
colostrum
scblc
human
rotaviru
hrv
induc
diarrhea
suckl
mice
litter
mice
oral
given
either
pb
n
solid
squar
dot
line
scblc
min
viral
inocul
fluoresc
cell
focusform
unit
fcfu
hrv
mo
strain
per
mous
viral
inocul
scblc
oral
given
gavag
time
h
postinocul
hpi
dosag
test
mg
n
open
diamond
mg
n
solid
triangl
mg
n
open
circl
stool
examin
daili
assess
diarrhea
hpi
diarrhea
character
use
diarrhea
index
di
normal
brown
form
stool
stool
soft
orang
stool
liquid
yellow
stool
point
repres
mean
sd
open
arrow
box
figur
indic
time
point
dose
scblc
administ
viral
inocul
close
arrow
indic
time
point
dose
scblc
administ
viral
inocul
p
p
determin
mannwhitney
u
test
panel
scblc
given
oral
gavag
time
h
postinocul
hpi
panel
b
scblc
given
oral
gavag
time
hpi
panel
c
scblc
given
oral
gavag
time
hpi
symptomat
diarrhea
express
percentag
mice
present
diarrhea
compar
total
mice
diarrhea
index
di
normal
brown
form
stool
stool
open
box
di
soft
brown
stool
gray
box
di
liquid
yellow
stool
black
box
remark
mic
igg
matur
milk
similar
inhibitori
activ
igg
scblc
therefor
antihrv
activ
scblc
depend
concentr
igg
present
sampl
determin
rotaviru
structur
protein
recogn
bovin
colostrum
igg
radiolabel
rotaviru
igg
mix
igg
collect
ripa
use
protein
gsepharos
obtain
iggprotein
gsepharos
analyz
sdspage
shown
figur
radiolabel
hrv
wa
strain
gave
major
band
almost
kda
band
like
outer
capsid
spike
middl
layer
smooth
surfac
glycoprotein
respect
est
cohen
case
bovin
rotaviru
ncdv
strain
similar
band
pattern
detect
figur
protein
locat
outer
capsid
viru
conclud
bovin
igg
protect
rotaviru
infect
neutral
viru
studi
compar
abil
igg
deriv
scblc
matur
milk
inhibit
hrvinduc
diarrhea
although
immunoglobulin
level
cow
milk
predict
declin
throughout
durat
lactat
antihrv
activ
igg
appear
hold
regardless
length
lactat
figur
furthermor
bovin
colostrum
igg
bind
rotaviru
detect
use
ripa
figur
although
efficaci
hyperimmun
bovin
colostrum
hrv
demonstr
clinic
trial
children
ebina
et
al
sarker
et
al
actual
use
limit
difficulti
largescal
product
thu
unimmun
scblc
produc
normal
healthi
cow
may
provid
altern
option
prevent
manag
sever
rotaviru
diarrhea
immunocompromis
children
furthermor
demonstr
multipl
administr
scblc
could
protect
symptom
hrv
infect
suckl
mice
first
confirm
prophylact
oral
singl
administr
scblc
dosag
greater
mg
min
viral
inocul
prevent
develop
diar
figur
comparison
antihuman
rotaviru
hrv
effect
igg
fraction
skim
concentr
bovin
late
colostrum
scblc
matur
milk
hrv
mo
strain
incub
sampl
min
inocul
virussampl
mixtur
ad
african
rhesu
monkey
cell
kidney
cell
line
mixtur
incub
co
atmospher
h
control
cell
prepar
way
except
preincub
occur
presenc
eagl
minim
essenti
medium
mem
contain
fetal
calf
serum
fc
concentr
sampl
given
logarithm
scale
scblc
open
squar
igg
scblc
scblc
igg
close
squar
matur
milk
open
triangl
igg
matur
milk
matur
milk
igg
close
triangl
inhibitori
activ
sampl
express
percentag
infect
cell
compar
control
cell
experi
carri
triplic
least
time
repres
result
sampl
given
mean
sd
figur
analysi
rotaviru
structur
protein
recogn
bovin
colostrum
igg
immunoglobulin
g
normal
bovin
colostrum
incub
slabel
rotaviru
virusigg
mixtur
purifi
use
protein
gsepharos
subject
sdspage
gradient
gel
imag
perform
bioimag
analyz
fujix
fujifilm
tokyo
japan
rhea
figur
second
examin
effect
alter
administr
frequenc
scblc
hrvinduc
diarrhea
five
administr
scblc
viral
inocul
hpi
dosag
mg
effect
greater
dosag
administ
fewer
time
ie
prophylact
singl
administr
potenti
reduc
develop
diarrhea
figur
result
also
indic
recoveri
diarrheal
symptom
relev
frequenc
administr
viru
inocul
especi
within
hpi
figur
addit
conclud
minimum
effect
dosag
multipl
administr
within
hpi
mg
figur
interestingli
guarino
et
al
report
serum
immunoglobulin
effect
rotaviru
infect
cell
monolay
model
vitro
experi
use
transepitheli
electr
resist
ter
show
addit
immunoglobulin
rotavirusinfect
cell
promot
restor
monolay
integr
serum
immunoglobulin
effect
timeand
dosagedepend
manner
henc
vivo
result
good
agreement
vitro
find
guarino
et
al
emphas
import
earli
treatment
hrv
infect
previou
studi
indic
rotaviru
infect
cell
caus
disrupt
tight
junction
loss
ter
cell
death
svensson
et
al
dickman
et
al
obert
et
al
ciarlet
et
al
cattosmith
et
al
onward
rotaviru
infect
contribut
significantli
alter
distribut
tight
junction
protein
occludin
obert
et
al
dickman
et
al
beau
et
dickman
et
al
dickman
et
al
cell
find
suggest
defens
disrupt
tight
junction
one
mechan
reliev
diarrheal
symptom
anoth
remark
observ
multipl
administr
hpi
onward
result
earlier
recoveri
hrvinduc
diarrhea
figur
previous
observ
scblc
prevent
heal
effect
intestin
injuri
induc
nonsteroid
antiinflammatori
drug
indomethacin
cairangzhuoma
et
al
taken
togeth
scblc
effect
reduc
sever
hrv
infect
compar
matur
milk
vitro
effect
attribut
antivir
titer
igg
quantiti
igg
regardless
lactat
period
suckl
mous
model
found
multipl
administr
lower
dosag
scblc
reliev
hrvinduc
diarrheal
symptom
conclud
key
reliev
diarrheal
symptom
administr
minimum
effect
dosag
scblc
earli
possibl
coupl
repetit
intak
durat
diarrhea
skim
concentr
bovin
late
colostrum
offer
promis
natur
treatment
option
hrv
infect
